*SI units recommended as per The International HbA1c Consensus.[29, 30] We suggest that aspirin therapy should not be routinely recommended
as the risk : benefit for primary prevention of CVD in patients with early (stage 1–3) CKD is uncertain (2C). We suggest that use of uric acid lowering agents (such as allopurinol, rasburicase or feboxostat) should not be routinely recommended in people with early (stages 1–3) CKD who have asymptomatic hyperuricaemia CCI-779 molecular weight (2C). a. We suggest vitamin D deficiency (25-hydroxyvitamin D <37.5 nmol/L) and insufficiency (25-hydroxyvitamin D 37.5–75 nmol/L), if present, be corrected using treatment strategies recommended for the general population (2C) as outlined below: b. We suggest a daily oral intake (total) of vitamin D for patients with early CKD
who are not exposed to direct sunlight for at least 1–2 h per week, as per NHMRC recommendations (2D). 19–50 years – 5 μg (200 IU) 51–70 years – 10 μg (400 IU) >70 years – 15 μg (600 IU) (where 1 μg = 40 IU) Note: Few foods contain significant amounts of vitamin D, the major sources being fatty fish (salmon, sardine, herring and mackerel), liver, www.selleckchem.com/products/mi-503.html eggs and fortified foods, such as margarine and some varieties of low-fat milk. There are limited data on vitamin D content of local foods. It is exceedingly difficult to obtain sufficient vitamin D from the diet alone. c. To strike a balance between achieving adequate vitamin D from sun exposure and avoiding the risk of skin cancer, we suggest that the recommendations made in the joint positions statements Progesterone of the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia, the Australasian College of Dermatologists and the Cancer Council of Australia be applied to patients with early chronic kidney disease (2D): Fair-skinned people can get enough vitamin D in summer from a few minutes
of sunlight on their face, arms and hands before 10:00 h or after 15:00 h on most days of the week. In winter in southern regions of Australia, when UV radiation levels are below 3, people need about 2–3 h of sunlight to their face, arms and hands over a week. Note: Endogenous synthesis (activation) of vitamin D is reduced in CKD, but it is not sure if extended sunlight exposure could overcome such insufficiency. d. We recommend a prescription of vitamin D therapy for early CKD patients with secondary hyperparathyroidism, as it has been shown to be effective in suppressing elevated levels of parathyroid hormone (PTH) (1A). Note: However, there has been insufficient evidence to date to determine whether this intervention improves patient-level outcomes (e.g. bone pain, fracture, need for parathyroidectomy, progression to renal replacement therapy, cardiovascular events or all-cause mortality).